Kathleen Drennan. Kathleen is a recognized leader in women’s health research, overseeing a number of high profile national studies for women involving heart disease, osteoporosis, obesity and estrogen replacement including the HERS and Pepi trials. An early supporter of Lucine, Kathleen leads the scientific advisory board. Ms. Drennan is the current and founding president of TrialAdvance. She has over 25 years of pharmaceutical research, clinical trial development and post-trial marketing experience. Prior to founding TrialAdvance, she was a managing director and SVP of Iris Global Clinical Trials Solutions and the founding president and COO of the renowned Chicago Center for Clinical Research where she developed the Rush-Presbyterian-St. Luke’s Medical Center as one of the largest and most successful independent research organizations in the country. In addition, Ms. Drennan was a founding and long-term board member of the Society for Women’s Health Research and is the Editor-in-Chief for Elsevier’s prestigious journal, Contemporary Clinical Trials.
Abraham Nagy MD. Dr. Abraham J. Nagy is the Medical Director of the Nevada Headache Institute. He is board certified in neurology by the American Board of Psychiatry and Neurology and fellowship-trained. Born and raised in Nevada, he attended Columbia University where he obtained a bachelor′s degree in Neuroscience. Dr. Nagy then returned to home for medical school at the University of Nevada School of Medicine before attending Yale University where he completed his Internship in Internal Medicine and Residency in Neurology. He obtained his fellowship in headache at the University College of London, Institute of Neurology, Queensquare London. From 2006 to 2009, Dr. Nagy was the Inpatient and Outpatient Clinical Director of the Headache Department at the University of California, San Francisco in the department of Neurology. In 2010, he returned home to Nevada to found the Nevada Headache Institute. Dr. Nagy is a member of the American Academy of Neurology, the American Headache Society and the International Headache Society. He serves on several American Headache Society and the American Academy of Neurology special interest sections and he is also an invited reviewer for the journals Cephalalgia and Headache. He has won several prestigious awards for his work, including the Clinical Headache Fellowship Award from the American Headache Society.
Orlandis Wells MD, FACOG. Dr. Wells, a native of Tallulah, Louisiana received his Medical Degree from Louisiana State University Health Science Center and completed Residency Training in OB/GYN through Louisiana State University’s affiliated healthcare systems, University Hospital and Charity Hospital of New Orleans. In 2003, he moved to Nevada and joined Southwest Medical and Associates, in 2005 he stepped into the world of private practice with the opening of Henderson OB/GYN. Dr. Wells is consistently rated by patients as one of the best physicians in Henderson.
Jeffrey Blaustein PhD. Dr. Blaustein is a recognized leader in the field of reproductive and behavioral neuroendocrinology. He founded the Center for Neuroendocrine Studies at the University of Massachusetts, Amherst. He has published over 140 articles in Behavioral Neuroendocrinology, steroid hormone influences on the brain. His neuroendocrine research has been consistently funded by the National Institutes of Health and/or the National Science Foundation for over 30 years. After serving as an editor of the Endocrine Society’s journal, Endocrinology, for five years, Dr. Blaustein is the Editor-in-Chief of the journal, and he currently serves and has served on the editorial boards of a number of other endocrine-related journals. He recently edited Behavioral Neuroendocrinology, Neurochemistry and Molecular Neurobiology, a volume of Handbook of Neurochemistry and Molecular Neurobiology. Dr. Blaustein is President-Elect of the Society for Behavioral Neuroendocrinology and he was a charter member of the Society for Women’s Health Research Isis Scientific Network on Sex, Gender, Drugs and the Brain.
Chad Cross BS, BS, MS, MS, PhD. Dr. Cross is a multidisciplinary scientist and holds advanced degrees in statistics, mathematics, biological sciences and counseling. He works primarily as a biostatistician, where he specializes in multivariate analysis, sampling, experimental design and the application of novel techniques to nonstandard data sets. Dr. Cross has 77 publications, four co-authored with Dr. Marrs, 42 professional presentations, and 16 funded grants. Dr. Cross recently retired from the UNLV school of Community Health Sciences as a tenured Associate Professor of Biostatistics. While at UNLV, he taught quantitative methods for over a decade and served as a statistical consultant/mentor for faculty and students in public health, psychology, counseling, environmental studies, mathematics, statistics, education, and the biological sciences. Dr. Cross currently works as a quantitative ecologist and statistician with a local consulting firm and as a biostatistical consultant with physicians, hospitals, and health professionals in Nevada. In addition to his statistical work, Dr. Cross is a psychotherapist in Las Vegas, and a managing member of Crossroads Wellness, LLC.
Les Goulden. Mr. Goulden brings over 35 years of immunoassay design, development and manufacturing experience. As a senior biopharmaceutical manufacturing executive at Johnson & Johnson, Beckman & Coulter, SmithKline and Monoclonal Antibodies, Mr. Goulden has helped design and oversee the commercialization and build manufacturing programs for hundreds of biologically based immunodiagnostics including the home pregnancy and home ovulation tests. Mr. Goulden directed the manufacturing startup division of SmithKline, taking the company from $1 million to over $50 million in sales. Similarly, Mr. Goulden was responsible for building Johnson & Johnson’s home pregnancy manufacturing division to $39 million in annual retail sales.
Ron Schoengold BS, MS, RAC. Mr. Schoengold brings over 25 years of biomedical regulatory expertise, with extensive experience in all phases of drug and medical device regulatory management. He is certified in regulatory affairs and has a proven track record for integrating quality and regulatory requirements with technical, organizational and business development needs. Mr. Schoengold has specialized training and hands-on experience in developing screening and diagnostic products in gastroenterology (e.g., Hemoccult® colorectal cancer screening tests), infectious disease and point-of-care (POC) devices, reagents and test systems. He is currently an advisor to the Larta Institute (National Institutes of Health, Commercialization Assistance Program) and assists companies awarded SBIR grants. Mr.Schoengold has published, presented or contributed to more than 16 scientific publications including a book chapter on POC testing, and holds 8 patents related to POC diagnostics. Mr. Schoengold earned a BS in biology and chemistry from St. John’s University and an MS in microbiology and biochemistry from Villanova University; and, he completed additional graduate studies in molecular biology, genetics and immunology at Bryn Mawr College.
Peng Ong BSEE , MS. Mr. Ong is a successful serial entrepreneur and brings valuable business and technology experience to the Lucine team. He was Co-Founder and Chief Architect of Electric Classifieds, Inc. – the creators of Match.com. As founding President and CEO of Interwoven, Inc. (now Autonomy), the leading provider of content infrastructure, Mr. Ong led the company to a successful IPO (NASDAQ: IWOV) in 1999. In 2002, he founded Encentuate, a provider of enterprise digital identity systems, which was acquired by IBM in 2008. Currently, Mr. Ong is the Chairman of Infocomm Investments Pte Ltd (IIPL), a venture fund with $200 million under management, which promotes innovative information and communication technology businesses in Singapore. Mr. Ong is also an independent board director of SingTel, a strategic consultant to The IBM Company, and on the Board of Trustees of Singapore University of Technology & Design. Mr. Ong received his BS in Electrical Engineering from University of Texas at Austin, and a MS in Computer Science from the University of Illinois at Urbana-Champaign.
John Philpott MBA. Mr. Philpott has over 20 years experience in the life science industry working with small late stage private and early stage public companies. After eight years in public accounting for Ernst & Young, Mr. Philpott joined Miravant Medical Technologies as CFO. As CFO, where he guided the company through multiple rounds of fundraising from start-up through IPO. Over the course of his tenure, he raised and managed over $300 million in equity, debt, partnering and licensing transactions. John oversaw all financial and corporate administrative activities including negotiations and financial management associated with joint ventures (Pharmacia and Guidant), licensing agreements and asset sales. Miravant’s executive team grew the business to 240 employees and four facilities. Following his eleven years at Miravant, Mr. Philpott joined Kreido Biofuels, Inc. He joined Kreido soon after their reverse merger into a public company and completed a $25 million PIPE. As CFO, he led the company’s financial management, including M&A activity. Mr. Philpott is currently part of the BioTuitive LLC group which provides consulting and business development activities for emerging life science and medical device technology/early stage companies. He is a CPA and has an MBA from UCLA.
Glenn Wilson BA. Mr. Wilson brings over 30 years of pharmaceutical and medical diagnostic development, operations and management experience to the Lucine team. He was involved with the start-up of two life science companies and has advised on many others. His first company Immulok, Inc. was acquired by Johnson & Johnson after three and a half years and provided 38X ROI. The second company, Miravant Medical Technologies, became a publicaly traded life sciences company and raised over $300mm in financing. During his tenure at Immulok, and then JNJ, Mr. Wilson developed and brought to market over 50 medical diagnostic products. While at Miravant, he guided photodynamic therapy through FDA approval. During his early career, Mr. Wilson worked at Endocrine Sciences developing polyclonal antibodies and hormone assays. He received a BA in Chemistry from University of California, San Diego.
Women’s Health Policy Advisors
Phyllis Greenberger MSW. Ms. Greenberger is the founding and current president and CEO of the renowned Society for Women’s Health Research (SWHR). SWHR is a Washington, D.C., based non-profit organization working to improve the health of all women through research, education and advocacy. Under Ms. Greenberger’s 20 years of leadership, SWHR has turned a national spotlight on women’s health, strengthening federal support for women’s initiatives and forcing recognition that sex differences are a critical factor in women’s health issues. Ms. Greenberger is one of the twenty most influential women in medicine today, according to The Medical Herald. She received a 2006 Red Dress Award from Women’s Day in recognition of her work in leading the way in the fight against heart disease in women and in 2010 Women’s Day named her one of 50 “Women Who Are Changing the World.” With Dr. Jennifer Wider, she is editor of SWHR’s book, “The Savvy Woman Patient: How and Why Your Sex Impacts Your Health,” a resource guide that details differences between women and men across major health areas. Ms. Greenberger is the recipient of numerous awards and serves on the Scientific Advisory Board for WomenHeart; is a board member of the Interstitial Cystitis Association; resides on the Editorial Board for Shape magazine; serves on the Women’s Task Force for the National Hemophilia Foundation; and is a member of the International Women’s Forum and the National Association of Professional Women. Ms. Greenberger received a BA from Syracuse University and an MSW from the Catholic University of America.